Dr. Zhang on Toxicities of Treatments in RCC | OncLive

Dr. Zhang on Toxicities of Treatments in RCC

January 9, 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Patients have tolerated immunotherapy very well in RCC, explains Zhang. There are current ongoing phase III trials investigating immunotherapy in combination with VEGF inhibitors randomized against sunitinib (Sutent) in the first-line setting.

Most of these trials have completely enrolled and are awaiting final results which will determine tolerability, explains Zhang.


x